<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-155737" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Voclosporin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Viraj R.</given-names>
          </name>
          <aff>Virginia Tech Carilion clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bankole</surname>
            <given-names>Adegbenga</given-names>
          </name>
          <aff>VTC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Viraj Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adegbenga Bankole declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-155737.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Voclosporin, a novel immunosuppressive medication, is approved for treating and managing lupus nephritis (LN) within the class of calcineurin inhibitors (CNIs). LN is a common manifestation of systemic lupus erythematosus (SLE), an autoimmune disease affecting various organs. Approximately 40% of SLE patients may develop LN. The primary goal of LN treatment is to preserve kidney function, reduce mortality, and improve the patient's quality of life while minimizing treatment-related adverse events. A timely response to therapy, as indicated by a reduction in proteinuria, may predict long-term outcomes, including the risk of SLE flares, end-stage kidney disease, and mortality. In the United States, voclosporin received FDA approval in 2021 for treating active LN in adults, combined with background immunosuppressive therapy. This CME activity overviews the indications, actions, and contraindications for voclosporin. It also emphasizes the mechanism of action, adverse event profile, and key factors such as dosing, pharmacokinetics, contraindications, and monitoring that are essential for healthcare team members involved in treating patients with lupus nephritis using voclosporin.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the signs and symptoms of LWE through careful patient assessment and evaluation.</p></list-item><list-item><p>Develop and implement appropriate treatment strategies and interventions tailored to the individual patient's needs.</p></list-item><list-item><p>Select and prescribe appropriate topical anti-inflammatories and ocular surface lubricants based on the severity and characteristics of LWE.</p></list-item><list-item><p>Effectively communicate with the patient, as well as other members of the healthcare team, to ensure a comprehensive understanding of LWE and its management plan.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=155737&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=155737">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-155737.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Voclosporin is a novel calcineurin inhibitor (CNI) that was developed and approved for treating lupus nephritis (LN). Voclosporin is a cyclosporine A analog with a modification of the functional group on the amino acid 1 residue.<xref ref-type="bibr" rid="article-155737.r1">[1]</xref>&#x000a0;The drug has an improved pharmacokinetic profile compared to other CNIs, such as cyclosporine, tacrolimus, and sirolimus.<xref ref-type="bibr" rid="article-155737.r1">[1]</xref><xref ref-type="bibr" rid="article-155737.r2">[2]</xref></p>
        <p>Voclosporin was approved by the Food and Drug Administration (FDA) in the USA on January 22, 2021, specifically for the treatment of adults with biopsy-proven lupus nephritis (LN) class III, IV, or V (class V alone or in combination with class III or IV). It is intended to be utilized in conjunction with background immunosuppressive therapy as part of the treatment regimen for LN.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
        <p>In Europe, voclosporin was approved by European Medicines Agency (EMA) on September 15, 2022. It is recommended by the European League Against Rheumatism and European Renal Association (EULAR/ERA) as an addition to a background regimen of mycophenolate mofetil and low-dose glucocorticoids in patients with LN.<xref ref-type="bibr" rid="article-155737.r4">[4]</xref>&#x000a0;The addition of voclosporin to background therapy significantly increases the chances of achieving the target urine/protein creatinine ratio at 3, 6, and 12 months.<xref ref-type="bibr" rid="article-155737.r1">[1]</xref></p>
      </sec>
      <sec id="article-155737.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Voclosporin is an oral CNI that binds cyclophilin A in T-cells.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref>&#x000a0;The drug molecule has a cyclic undecapeptide structure of 11 amino acids, originally isolated from a fungus species named Beauveria nivea.<xref ref-type="bibr" rid="article-155737.r5">[5]</xref><xref ref-type="bibr" rid="article-155737.r6">[6]</xref>&#x000a0;There is an additional single carbon extension to the amino acid-1 position.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref> This structural change results in a molecule with higher binding potency to cyclophilin A and increased inhibition of calcineurin.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref> The voclosporin-cyclophilin binding competitively inhibits calcineurin from dephosphorylating the nuclear factor of activated T-cells (NFAT-P) to the nuclear factor of activated T-cells (NFAT).<xref ref-type="bibr" rid="article-155737.r2">[2]</xref>&#x000a0;</p>
        <p>Inhibition of this critical metabolic step precludes NFAT from activating the translation and transcription of various cytokines produced by T-helper-1 cells, including interleukin-2 (IL-2). IL-2 is a T-cell growth factor vital for the proliferation of T cells and for the generation of effector and memory cells.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r8">[8]</xref><xref ref-type="bibr" rid="article-155737.r9">[9]</xref>&#x000a0;The inhibited production of IL-2 prevents the proliferation and differentiation of cytotoxic and other effector T cells.<xref ref-type="bibr" rid="article-155737.r7">[7]</xref><xref ref-type="bibr" rid="article-155737.r9">[9]</xref></p>
        <p>Activated calcineurin dephosphorylates synaptopodin which is then metabolized by a lysosomal protease.<xref ref-type="bibr" rid="article-155737.r10">[10]</xref>&#x000a0;This breakdown ultimately results in the destabilization of the podocyte cytoskeleton and increases proteinuria.<xref ref-type="bibr" rid="article-155737.r7">[7]</xref><xref ref-type="bibr" rid="article-155737.r10">[10]</xref>&#x000a0;Voclosporin, by inhibiting this dephosphorylation pathway, promotes actin cytoskeleton stabilization of the podocytes and thus reduces proteinuria.<xref ref-type="bibr" rid="article-155737.r8">[8]</xref>&#x000a0;Voclosporin inhibits the dephosphorylation pathway by binding the phosphorylated synaptopodin with the 14-3-3 protein.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref><xref ref-type="bibr" rid="article-155737.r10">[10]</xref>&#x000a0;</p>
        <p>The modification of amino acid-1 changes the primary site of metabolism to the amino acid-9 position. The modification results in a lower degree of competitive inhibition and a low metabolite load.<xref ref-type="bibr" rid="article-155737.r5">[5]</xref><xref ref-type="bibr" rid="article-155737.r11">[11]</xref>&#x000a0;This favorable metabolic profile also improves serum drug levels in a dose-proportional manner over a wide therapeutic range. This particular property means that therapeutic drug monitoring is not required for voclosporin.<xref ref-type="bibr" rid="article-155737.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The major circulating component is voclosporin. A major metabolite of voclosporin with approximately 8-fold less potency than the parent molecule represented about 16.7% of total exposure in whole human blood.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref> Around 99% of the drug is metabolized via cytochrome P450 3A4 (CYP3A4) isoform and excreted in feces, as confirmed after administration of radiolabeled voclosporin.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
        <p>After six days of twice daily dosing, voclosporin can achieve steady-state concentrations.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref> The maximum concentration (Cmax) of voclosporin can be reached within 1 to 4 hours if taken on an empty stomach.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref> The pharmacokinetics of voclosporin is not influenced by age, gender, body weight, race, total bilirubin, and serum albumin in a clinically relevant manner.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref>&#x000a0;There was no significant lag between the interval taken to reach maximum voclosporin concentrations and the time taken for maximum inhibition of calcineurin.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref><xref ref-type="bibr" rid="article-155737.r12">[12]</xref>&#x000a0;</p>
        <p>When administered with low- or high-fat meals in healthy adults, Cmax decreases by 29% to 53%.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref> Voclosporin distributes extensively in red blood cells. The distribution between whole blood and plasma is dependent on concentration and temperature.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref> Given voclosporin&#x02019;s high protein binding of 97%, its apparent volume of distribution of 2154 Liters. Voclosporin&#x02019;s mean apparent clearance is 63.6 L/h at steady-state with a mean terminal half-life of around 30 hours.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
      </sec>
      <sec id="article-155737.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Voclosporin is dosed and administered in the following manner:</p>
        <p>In adults with active lupus nephritis, when combined with background immunosuppressive therapy:</p>
        <list list-type="bullet">
          <list-item>
            <p>23.7 mg twice daily by mouth. To ensure adequate absorption, voclosporin must be taken on an empty stomach.<xref ref-type="bibr" rid="article-155737.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>Dose adjustments may be necessary for patients with renal dysfunction and are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>If eGFR is &#x0003c;60 mL/min/1.73 m<sup>2</sup> and reduced from baseline by &#x0003e;20% and &#x0003c;30%, the dose should be reduced by 7.9 mg twice daily.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Upon re-assessing the eGFR within&#x000a0;2 weeks, if it is still reduced from baseline by &#x0003e;20%, reduce the dose again by 7.9 mg twice daily.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>If eGFR is &#x0003c;60 mL/min/1.73 m<sup>2</sup> and reduced from baseline by &#x0003e;30%, voclosporin should be discontinued.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>For patients with a decrease in dose due to eGFR, consider increasing the dose by 7.9 mg twice daily for each eGFR measurement that is &#x02265;80% of baseline; do not exceed the starting dose.</p>
          </list-item>
          <list-item>
            <p>If voclosporin is used in patients with severe renal impairment at baseline (creatinine clearance &#x0003c;30 mL/min the recommended starting dose is 15.8 mg twice a day.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with end-stage renal disease (ESRD) with or without hemodialysis, the pharmacokinetics of voclosporin is unknown.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Dose adjustments may be necessary for patients with hepatic dysfunction and are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with mild and moderate hepatic impairment (Child-Pugh A and Child-Pugh B), the recommended dose is 15.8 mg twice daily.</p>
          </list-item>
          <list-item>
            <p>Voclosporin is not recommended in patients with severe hepatic impairment (Child-Pugh C).</p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Voclosporin is a CYP3A4 substrate. When co-administered with other medications that are moderate or potent CYP3A4 inhibitors, it reduces clearance and increases voclosporin levels. The increased levels can increase the risk of voclosporin-associated adverse reactions.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>AReducingthe dose of voclosporin is recommended when co-administered with moderate CYP3A4 inhibitors such as verapamil, fluconazole, and diltiazem.<xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>When voclosporin is co-administered with moderate or strong CYP3A4 inducers, the combination increases voclosporin metabolism, reducing the efficacy of voclosporin.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Voclosporin is an inhibitor of P-glycoprotein (P-gp). Hence, caution is required upon co-administration with other P-gp inhibitors such as verapamil, sertraline, erythromycin, and reserpine. If P-gp substrates with a narrow therapeutic index, such as digoxin, are co-administered with voclosporin, then a dose reduction of P-gb substrates may be required.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>There is no clinically significant interaction between voclosporin and mycophenolate mofetil. There is no necessity for dose adjustment when these medications are administered simultaneously.<xref ref-type="bibr" rid="article-155737.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-155737.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Voclosporin, similar to other CNIs, can cause acute and chronic nephrotoxicity. The major adverse effect of voclosporin is reduced glomerular filtration rate. Nephrotoxicity is usually dose-dependent and can be influenced by drug&#x02013;drug interactions and intracellular concentrations. Acute nephrotoxicity can be caused by a reversible glomerular filtration rate (GFR) decrease. Chronic nephrotoxicity can be marked by nonspecific arteriolar lesions, focal and segmental and global glomerular sclerosis, patchy interstitial fibrosis, and tubular atrophy, which can progress to irreversible lesions.<xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
        <p>Hypertension is a common adverse effect of voclosporin; it can be explained by the vasoconstrictive effect of voclosporin on afferent pre-glomerular arterioles.&#x000a0;Hypertension also contributes to decreased eGFR and subsequent salt and water retention. Arterial hypertension is less severe with voclosporin when compared to other CNIs.<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref><xref ref-type="bibr" rid="article-155737.r11">[11]</xref></p>
        <p>Voclosporin can cause neurotoxicity, including posterior reversible encephalopathy syndrome (PRES), delirium, seizure, coma, tremors, paresthesia, headache, and mental status changes.<xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
        <p>Although clinically apparent acute liver injury with jaundice has not been classically linked to voclosporin, it can be associated with a low rate of transient serum enzyme elevations during treatment.<xref ref-type="bibr" rid="article-155737.r6">[6]</xref></p>
        <p>Electrolyte disturbances of hyperkalemia and hypomagnesemia can occur with the administration of calcineurin inhibitors, including voclosporin. Hypomagnesemia can be caused by reduced renal reabsorption of magnesium and chronic renal magnesium wasting. Due to the inhibition of calcineurin, there is reduced expression of Na-K-2Cl-cotransporter on the tubular epithelial cells, which plays a role in hyperkalemia. These electrolyte abnormalities may be responsible for voclosporin prolonging QTc interval. Dose-dependent QTc prolongation was noted after a single dose of voclosporin 0.5&#x000a0;to 4.5 mg/kg (which is up to 9-fold higher than the therapeutic dose).<xref ref-type="bibr" rid="article-155737.r2">[2]</xref><xref ref-type="bibr" rid="article-155737.r12">[12]</xref><xref ref-type="bibr" rid="article-155737.r13">[13]</xref></p>
        <p>The exact association between pure red cell aplasia (PRCA) and voclosporin is unknown. If a patient develops PRCA while on treatment with voclosporin, the discontinuation of voclosporin should be considered. Voclosporin may increase the risk of developing lymphomas and malignancies predominantly of the skin.<xref ref-type="bibr" rid="article-155737.r4">[4]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
        <p>Other adverse effects reported with voclosporin are as follows, and these can be approached on a case-by-case basis, weighing the benefits and the risks.</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Nausea with vomiting</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Cough</p>
          </list-item>
          <list-item>
            <p>Increased risk of infections such as upper respiratory tract infections</p>
          </list-item>
          <list-item>
            <p>Peripheral edema</p>
          </list-item>
          <list-item>
            <p>Alopecia</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-155737.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>The co-administration of voclosporin with potent CYP3A4 inhibitors, for example, ketoconazole, itraconazole, and clarithromycin, are contraindicated.<xref ref-type="bibr" rid="article-155737.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with eGFR &#x0003c;45 mL/min/1.73 m<sup>2</sup>, using voclosporin is contraindicated unless benefits exceed risks.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref><xref ref-type="bibr" rid="article-155737.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Voclosporin is not recommended in patients with hypertension with a baseline blood pressure of &#x0003e;165/105 mm Hg.<xref ref-type="bibr" rid="article-155737.r3">[3]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Although there is not much data about the use of voclosporin in pregnant women and lactating women, voclosporin formulation contains alcohol, and the current recommendation is that voclosporin should be avoided in pregnant and lactating patients.<xref ref-type="bibr" rid="article-155737.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-155737.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient's blood pressure should also be recorded before treatment initiation and monitored biweekly for the first month of treatment. After which, it should be monitored as indicated clinically.<xref ref-type="bibr" rid="article-155737.r5">[5]</xref><xref ref-type="bibr" rid="article-155737.r7">[7]</xref></p>
        <p>An accurate baseline estimated glomerular filtration rate (eGFR) should be established before initiating voclosporin, and eGFR should be assessed every&#x000a0;2 weeks for the first month of treatment and every&#x000a0;4 weeks after that.<xref ref-type="bibr" rid="article-155737.r13">[13]</xref></p>
        <p>Voclosporin and mycophenolate mofetil (MMF) can be administered concomitantly without adjusting the dose of MMF. There is no risk of the emergence of MMF-related adverse effects following the discontinuation of voclosporin.<xref ref-type="bibr" rid="article-155737.r4">[4]</xref></p>
      </sec>
      <sec id="article-155737.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In the event of overdose or toxicity, there are currently no reversal agents approved for voclosporin&#x000a0;by the FDA. The FDA-boxed warnings include an increased risk of developing serious infections and malignancies.</p>
      </sec>
      <sec id="article-155737.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of autoimmune diseases, such as SLE/LN, is a complex process that imposes a significant cost burden on both patients and the healthcare system. Voclosporin, a novel immunosuppressive agent, is used in combination with background immunosuppressive therapy for patients with lupus nephritis. The utilization of background immunosuppressive therapies in conjunction with voclosporin is a critical aspect of LN management.</p>
        <p>To ensure the best possible outcomes for patients, an interprofessional healthcare team comprising various specialties is essential. Despite the improved pharmacodynamics of voclosporin compared to previous calcineurin inhibitors (CNIs), it can still lead to severe adverse effects. Therefore, regular patient visits and frequent monitoring of vital signs and laboratory tests are crucial to prevent potential complications. Primary care providers, including&#x000a0;advanced practice practitioners,&#x000a0;should be well-informed about significant adverse effects and maintain open communication with rheumatologists and nephrologists to address any concerns that may arise.</p>
        <p>Given the potential for drug interactions, collaborative patient care involving pharmacists is paramount. Accurate and comprehensive medication reconciliation, along with verification of the appropriate dose adjusted for creatinine clearance, should be conducted by pharmacists. If any discrepancies are noted, they should promptly communicate them to other members of the healthcare team.</p>
        <p>Close monitoring for adverse effects is necessary for all patients receiving voclosporin, and nurses often play a key role in being the first to receive reports of adverse events from patients. This information can then be shared with other members of the healthcare team for collaborative decision-making regarding further steps. Social workers have a crucial role in identifying barriers to care, including financial constraints that may hinder medication affordability. The social work team can provide the necessary resources and support to assist patients in overcoming these challenges.</p>
        <p>In summary, the use of voclosporin in the treatment of lupus nephritis requires an interprofessional healthcare team consisting of physicians, physician extenders, nurses, pharmacists, and social workers. Although team members come from various disciplines, effective collaboration and communication are essential to achieve optimal outcomes for patients.[Level 5]</p>
      </sec>
      <sec id="article-155737.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=155737&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=155737">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/155737/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=155737">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-155737.s11">
        <title>References</title>
        <ref id="article-155737.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <name>
                <surname>Ginzler</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Arriens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caster</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Romero-Diaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lisk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Navarra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Solomons</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>May</month>
            <day>29</day>
            <volume>397</volume>
            <issue>10289</issue>
            <fpage>2070</fpage>
            <page-range>2070-2080</page-range>
            <pub-id pub-id-type="pmid">33971155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McArn</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Nixon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jarrell</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2022</year>
            <month>Feb</month>
            <day>15</day>
            <fpage>10600280221075331</fpage>
            <pub-id pub-id-type="pmid">35168373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heo</surname>
                <given-names>YA</given-names>
              </name>
            </person-group>
            <article-title>Voclosporin: First Approval.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>605</fpage>
            <page-range>605-610</page-range>
            <pub-id pub-id-type="pmid">33788181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Gelder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Lisk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Solomons</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2022</year>
            <month>Apr</month>
            <day>25</day>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>917</fpage>
            <page-range>917-922</page-range>
            <pub-id pub-id-type="pmid">33527141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Gelder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lerma</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Engelke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2022</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>515</fpage>
            <page-range>515-529</page-range>
            <pub-id pub-id-type="pmid">35763288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <chapter-title>Voclosporin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>8</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">34570445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reggiani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moroni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Old and New Calcineurin Inhibitors in Lupus Nephritis.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Oct</month>
            <day>21</day>
            <volume>10</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">34768354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bankole</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nwaonu</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>The Shifting Landscape of Lupus Nephritis Management: A Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>e20950</fpage>
            <pub-id pub-id-type="pmid">35154930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Signaling and Function of Interleukin-2 in T Lymphocytes.</article-title>
            <source>Annu Rev Immunol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>26</day>
            <volume>36</volume>
            <fpage>411</fpage>
            <page-range>411-433</page-range>
            <pub-id pub-id-type="pmid">29677473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Phosphorylation of key podocyte proteins and the association with proteinuric kidney disease.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>319</volume>
            <issue>2</issue>
            <fpage>F284</fpage>
            <page-range>F284-F291</page-range>
            <pub-id pub-id-type="pmid">32686524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Palmisano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies.</article-title>
            <source>Clin Pharmacol</source>
            <year>2020</year>
            <volume>12</volume>
            <fpage>83</fpage>
            <page-range>83-96</page-range>
            <pub-id pub-id-type="pmid">32669879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yap</surname>
                <given-names>DYH</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Novel and emerging treatment strategies for lupus nephritis.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>1283</fpage>
            <page-range>1283-1292</page-range>
            <pub-id pub-id-type="pmid">36260817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lech</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gaikwad</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.</article-title>
            <source>BioDrugs</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-475</page-range>
            <pub-id pub-id-type="pmid">37093522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alamilla-Sanchez</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Alcala-Salgado</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alonso-Bello</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Fonseca-Gonzalez</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>441</fpage>
            <page-range>441-458</page-range>
            <pub-id pub-id-type="pmid">34924767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ling</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Larouche</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Aspeslet</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>1039</fpage>
            <page-range>1039-50</page-range>
            <pub-id pub-id-type="pmid">24330024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155737.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dao</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Bermas</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Systemic Lupus Erythematosus Management in Pregnancy.</article-title>
            <source>Int J Womens Health</source>
            <year>2022</year>
            <volume>14</volume>
            <fpage>199</fpage>
            <page-range>199-211</page-range>
            <pub-id pub-id-type="pmid">35210867</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
